<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en" dir="ltr">
  <head>
    <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" />
    		<meta name="keywords" content="Atrial fibrillation,Alcoholic beverage,American College of Cardiology,American Heart Association,Amiodarone,Angina,Antiarrhythmic agent,Anticoagulant,Anticoagulation,As of 2005,Ashman phenomenon" />
		<link rel="shortcut icon" href="/favicon.ico" />
		<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (English)" />
		<link rel="copyright" href="../../../COPYING.html" />
    <title>Atrial fibrillation - Wikipedia, the free encyclopedia</title>
    <style type="text/css">/*<![CDATA[*/ @import "../../../skins/htmldump/main.css"; /*]]>*/</style>
    <link rel="stylesheet" type="text/css" media="print" href="../../../skins/common/commonPrint.css" />
    <!--[if lt IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE50Fixes.css";</style><![endif]-->
    <!--[if IE 5.5000]><style type="text/css">@import "../../../skins/monobook/IE55Fixes.css";</style><![endif]-->
    <!--[if IE 6]><style type="text/css">@import "../../../skins/monobook/IE60Fixes.css";</style><![endif]-->
    <!--[if IE]><script type="text/javascript" src="../../../skins/common/IEFixes.js"></script>
    <meta http-equiv="imagetoolbar" content="no" /><![endif]-->
    <script type="text/javascript" src="../../../skins/common/wikibits.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/md5.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/utf8.js"></script>
    <script type="text/javascript" src="../../../skins/htmldump/lookup.js"></script>
    <script type="text/javascript" src="../../../raw/gen.js"></script>        <style type="text/css">/*<![CDATA[*/
@import "../../../raw/MediaWiki%7ECommon.css";
@import "../../../raw/MediaWiki%7EMonobook.css";
@import "../../../raw/gen.css";
/*]]>*/</style>          </head>
  <body
    class="ns-0">
    <div id="globalWrapper">
      <div id="column-content">
	<div id="content">
	  <a name="top" id="contentTop"></a>
	        <h1 class="firstHeading">Atrial fibrillation</h1>
	  <div id="bodyContent">
	    <h3 id="siteSub">From Wikipedia, the free encyclopedia</h3>
	    <div id="contentSub"></div>
	    	    <div class="usermessage">You have <a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">new messages</a> (<a href="../../../1/2/7/User_talk%7E127.0.0.1.html" title="User talk:127.0.0.1">last change</a>).</div>	    <!-- start content -->
	    <table class="infobox" style="width: 200px; font-size: 95%; text-align: left;">
<caption style="background: lightgrey; font-size: 95%;"><b>Atrial fibrillation</b><br />
<i>Classification &amp; external resources</i></caption>
<tr>
<th colspan="2" style="text-align: center; font-size: smaller;">
<div class="center">
<div class="floatnone"><span><a href="../../../s/i/n/Image%7ESinusRhythmLabels.svg_efb5.html" class="image" title=""><img src="../../../upload/thumb/9/9e/SinusRhythmLabels.svg/190px-SinusRhythmLabels.svg.png" alt="" width="190" height="187" longdesc="../../../s/i/n/Image%7ESinusRhythmLabels.svg_efb5.html" /></a></span></div>
</div>
</th>
</tr>
<tr style="line-height: 1;">
<td colspan="2" style="text-align:center;"><small>The P waves, which represent depolarization of the atria, are irregular or absent during atrial fibrillation.</small></td>
</tr>
<tr>
<th><a href="../../../i/c/d/ICD_10d0.html" title="ICD">ICD</a>-<a href="../../../l/i/s/List_of_ICD-10_codes_1183.html" title="List of ICD-10 codes">10</a></th>
<td><a href="../../../i/c/d/ICD-10_Chapter_I_77b5.html" title="ICD-10 Chapter I">I</a><a href="http://www.who.int/classifications/apps/icd/icd10online/?gi30.htm+i48" class="external text" title="http://www.who.int/classifications/apps/icd/icd10online/?gi30.htm+i48" rel="nofollow">48.</a></td>
</tr>
<tr>
<th><a href="../../../i/c/d/ICD_10d0.html" title="ICD">ICD</a>-<a href="../../../l/i/s/List_of_ICD-9_codes_cdaa.html" title="List of ICD-9 codes">9</a></th>
<td><a href="http://www.icd9data.com/getICD9Code.ashx?icd9=427.31" class="external text" title="http://www.icd9data.com/getICD9Code.ashx?icd9=427.31" rel="nofollow">427.31</a></td>
</tr>
<tr>
<th><a href="../../../d/i/s/Diseases_Database_9859.html" title="Diseases Database">DiseasesDB</a></th>
<td><a href="http://www.diseasesdatabase.com/ddb1065.htm" class="external text" title="http://www.diseasesdatabase.com/ddb1065.htm" rel="nofollow">1065</a></td>
</tr>
<tr>
<th><a href="../../../m/e/d/MedlinePlus_0b70.html" title="MedlinePlus">MedlinePlus</a></th>
<td><a href="http://www.nlm.nih.gov/medlineplus/ency/article/000184.htm" class="external text" title="http://www.nlm.nih.gov/medlineplus/ency/article/000184.htm" rel="nofollow">000184</a></td>
</tr>
<tr>
<th><a href="../../../e/m/e/EMedicine_a89c.html" title="EMedicine">eMedicine</a></th>
<td><a href="http://www.emedicine.com/med/topic184.htm" class="external text" title="http://www.emedicine.com/med/topic184.htm" rel="nofollow">med/184</a>&#160; <a href="http://www.emedicine.com/emerg/topic46.htm" class="external text" title="http://www.emedicine.com/emerg/topic46.htm" rel="nofollow">emerg/46</a></td>
</tr>
</table>
<p><b>Atrial fibrillation</b> (<b>AF</b> or <b>afib</b>) is an abnormal <a href="../../../h/e/a/Heart.html" title="Heart">heart</a> rhythm (<a href="../../../c/a/r/Cardiac_arrhythmia.html" title="Cardiac arrhythmia">cardiac arrhythmia</a>) which involves the two small, upper heart chambers (the <a href="../../../a/t/r/Atrium_%28anatomy%29.html" title="Atrium (anatomy)">atria</a>). <a href="../../../h/e/a/Heart_rate.html" title="Heart rate">Heart beats</a> in a normal heart begin after <a href="../../../e/l/e/Electricity.html" title="Electricity">electricity</a> generated in the atria by the <a href="../../../s/i/n/Sinoatrial_node.html" title="Sinoatrial node">sinoatrial node</a> spreads through the heart and causes contraction of the heart muscle and pumping of <a href="../../../b/l/o/Blood.html" title="Blood">blood</a>. In AF, the regular electrical impulses of the sinoatrial node are replaced by disorganized, rapid electrical impulses which result in irregular heart beats.</p>
<p>Atrial fibrillation is the most common cardiac arrhythmia. The risk of developing atrial fibrillation increases with age — AF affects four percent of individuals in their 80s. An individual may spontaneously alternate between AF and a normal rhythm (<i>paroxysmal atrial fibrillation</i>) or may continue with AF as the dominant cardiac rhythm without reversion to the normal rhythm (<i>chronic atrial fibrillation</i>). This variety of disorder is sometimes associated with the secretion of adrenalin under conditions of emotional stress in this age group.</p>
<p>Atrial fibrillation is often asymptomatic, but may result in symptoms of <a href="../../../p/a/l/Palpitations.html" title="Palpitations">palpitations</a>, <a href="../../../f/a/i/Fainting.html" title="Fainting">fainting</a>, <a href="../../../a/n/g/Angina.html" title="Angina">chest pain</a>, or even <a href="../../../c/o/n/Congestive_heart_failure.html" title="Congestive heart failure">heart failure</a>. These symptoms are especially common when atrial fibrillation results in a heart rate which is either too fast or too slow. In addition, the erratic motion of the atria leads to blood stagnation (<a href="../../../s/t/a/Stasis.html" title="Stasis">stasis</a>) which increases the risk of <a href="../../../t/h/r/Thrombosis.html" title="Thrombosis">blood clots</a> that may travel from the heart to the <a href="../../../b/r/a/Brain.html" title="Brain">brain</a> and other areas. Thus, AF is an important risk factor for <a href="../../../c/e/r/Cerebrovascular_accident.html" title="Cerebrovascular accident">stroke</a>, the most feared complication of atrial fibrillation.</p>
<p>The symptoms of atrial fibrillation may be treated with medications which slow the heart rate. Several medications as well as electrical <a href="../../../c/a/r/Cardioversion.html" title="Cardioversion">cardioversion</a> may be used to convert AF to a normal heart rhythm. Surgical and catheter-based therapies may also be used to prevent atrial fibrillation in certain individuals. People with AF are often given <a href="../../../a/n/t/Anticoagulant.html" title="Anticoagulant">blood thinners</a> such as <a href="../../../w/a/r/Warfarin.html" title="Warfarin">warfarin</a> to protect them from strokes.</p>
<table id="toc" class="toc" summary="Contents">
<tr>
<td>
<div id="toctitle">
<h2>Contents</h2>
</div>
<ul>
<li class="toclevel-1"><a href="#Classification"><span class="tocnumber">1</span> <span class="toctext">Classification</span></a>
<ul>
<li class="toclevel-2"><a href="#First_Detected"><span class="tocnumber">1.1</span> <span class="toctext">First Detected</span></a></li>
<li class="toclevel-2"><a href="#Recurrent"><span class="tocnumber">1.2</span> <span class="toctext">Recurrent</span></a></li>
<li class="toclevel-2"><a href="#Lone_atrial_fibrillation"><span class="tocnumber">1.3</span> <span class="toctext">Lone atrial fibrillation</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Signs_and_symptoms"><span class="tocnumber">2</span> <span class="toctext">Signs and symptoms</span></a></li>
<li class="toclevel-1"><a href="#Diagnosis"><span class="tocnumber">3</span> <span class="toctext">Diagnosis</span></a>
<ul>
<li class="toclevel-2"><a href="#Electrocardiogram"><span class="tocnumber">3.1</span> <span class="toctext">Electrocardiogram</span></a></li>
<li class="toclevel-2"><a href="#Other_investigations"><span class="tocnumber">3.2</span> <span class="toctext">Other investigations</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Causes"><span class="tocnumber">4</span> <span class="toctext">Causes</span></a></li>
<li class="toclevel-1"><a href="#Pathophysiology"><span class="tocnumber">5</span> <span class="toctext">Pathophysiology</span></a></li>
<li class="toclevel-1"><a href="#Treatment"><span class="tocnumber">6</span> <span class="toctext">Treatment</span></a>
<ul>
<li class="toclevel-2"><a href="#Rate_control"><span class="tocnumber">6.1</span> <span class="toctext">Rate control</span></a></li>
<li class="toclevel-2"><a href="#Rhythm_control"><span class="tocnumber">6.2</span> <span class="toctext">Rhythm control</span></a>
<ul>
<li class="toclevel-3"><a href="#Radiofrequency_ablation"><span class="tocnumber">6.2.1</span> <span class="toctext">Radiofrequency ablation</span></a></li>
<li class="toclevel-3"><a href="#Cox_maze_Procedure"><span class="tocnumber">6.2.2</span> <span class="toctext">Cox maze Procedure</span></a></li>
<li class="toclevel-3"><a href="#Minimaze_surgical_procedures"><span class="tocnumber">6.2.3</span> <span class="toctext">Minimaze surgical procedures</span></a></li>
</ul>
</li>
<li class="toclevel-2"><a href="#Anticoagulation"><span class="tocnumber">6.3</span> <span class="toctext">Anticoagulation</span></a></li>
</ul>
</li>
<li class="toclevel-1"><a href="#Prognosis"><span class="tocnumber">7</span> <span class="toctext">Prognosis</span></a></li>
<li class="toclevel-1"><a href="#Epidemiology"><span class="tocnumber">8</span> <span class="toctext">Epidemiology</span></a></li>
<li class="toclevel-1"><a href="#History"><span class="tocnumber">9</span> <span class="toctext">History</span></a></li>
<li class="toclevel-1"><a href="#See_also"><span class="tocnumber">10</span> <span class="toctext">See also</span></a></li>
<li class="toclevel-1"><a href="#Notes_and_references"><span class="tocnumber">11</span> <span class="toctext">Notes and references</span></a></li>
<li class="toclevel-1"><a href="#External_links"><span class="tocnumber">12</span> <span class="toctext">External links</span></a></li>
</ul>
</td>
</tr>
</table>
<p><script type="text/javascript">
//<![CDATA[
 if (window.showTocToggle) { var tocShowText = "show"; var tocHideText = "hide"; showTocToggle(); } 
//]]>
</script><a name="Classification" id="Classification"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Classification">edit</a>]</span> <span class="mw-headline">Classification</span></h2>
<p>The <a href="../../../a/m/e/American_Heart_Association_032c.html" title="American Heart Association">American Heart Association</a>, <a href="../../../a/m/e/American_College_of_Cardiology_d1c5.html" title="American College of Cardiology">American College of Cardiology</a>, and the <a href="../../../e/u/r/European_Society_of_Cardiology_8629.html" title="European Society of Cardiology">European Society of Cardiology</a> have proposed the following classification system based on simplicity and clinical relevance.<sup id="_ref-0" class="reference"><a href="#_note-0" title="">[1]</a></sup></p>
<p><a name="First_Detected" id="First_Detected"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: First Detected">edit</a>]</span> <span class="mw-headline">First Detected</span></h3>
<p>Any patient newly diagnosed with atrial fibrillation fits in this category, as the exact onset and chronicity of the disease is often uncertain.</p>
<p><a name="Recurrent" id="Recurrent"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Recurrent">edit</a>]</span> <span class="mw-headline">Recurrent</span></h3>
<p>Any patient with 2 or more identified episodes of atrial fibrillation is said to have recurrent atrial fibrillation. This is further classified into paroxysmal and persistent based on when the episode terminates without therapy. Atrial fibrillation is said to be paroxysmal when it terminates spontaneously within 7 days, most commonly within 24 hours. Persistent or chronic atrial fibrillation is AF established for more than seven days. Differentiation of paroxysmal from chronic or established AF is based on the history of recurrent episodes and the duration of the current episode of AF.<sup id="_ref-1" class="reference"><a href="#_note-1" title="">[2]</a></sup><sup id="_ref-2" class="reference"><a href="#_note-2" title="">[3]</a></sup></p>
<p><a name="Lone_atrial_fibrillation" id="Lone_atrial_fibrillation"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Lone atrial fibrillation">edit</a>]</span> <span class="mw-headline">Lone atrial fibrillation</span></h3>
<p>Lone atrial fibrillation (LAF) is defined as atrial fibrillation in the absence of clinical or echocardiographic findings of cardiopulmonary disease.<sup id="_ref-3" class="reference"><a href="#_note-3" title="">[4]</a></sup> Patients with LAF who are under 65 have the best prognosis.</p>
<p><a name="Signs_and_symptoms" id="Signs_and_symptoms"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Signs and symptoms">edit</a>]</span> <span class="mw-headline">Signs and symptoms</span></h2>
<p>Atrial fibrillation is usually accompanied by symptoms related to either the rapid heart rate or <a href="../../../e/m/b/Embolization.html" title="Embolization">embolization</a>. Rapid and irregular heart rates may be perceived as <a href="../../../p/a/l/Palpitations.html" title="Palpitations">palpitations</a>, exercise intolerance, and occasionally produce <a href="../../../a/n/g/Angina.html" title="Angina">angina</a> and congestive symptoms of shortness of breath or <a href="../../../e/d/e/Edema.html" title="Edema">edema</a>. Sometimes the arrhythmia will be identified with the onset of a stroke or a <a href="../../../t/r/a/Transient_ischemic_attack.html" title="Transient ischemic attack">transient ischemic attack</a> (TIA). It is not uncommon to identify atrial fibrillation on a routine physical examination or <a href="../../../e/l/e/Electrocardiogram.html" title="Electrocardiogram">electrocardiogram</a> (ECG/EKG), as it may be asymptomatic in some cases.</p>
<p><i>Paroxysmal</i> atrial fibrillation is the episodic occurrence of the arrhythmia and may be difficult to diagnose. Episodes may occur with sleep or with exercise, and their episodic nature may require prolonged ECG monitoring (e.g. a <a href="../../../h/o/l/Holter_monitor.html" title="Holter monitor">Holter monitor</a>) for diagnosis.</p>
<p><a name="Diagnosis" id="Diagnosis"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Diagnosis">edit</a>]</span> <span class="mw-headline">Diagnosis</span></h2>
<p><a name="Electrocardiogram" id="Electrocardiogram"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Electrocardiogram">edit</a>]</span> <span class="mw-headline">Electrocardiogram</span></h3>
<div class="thumb tright">
<div class="thumbinner" style="width:402px;"><a href="../../../a/f/i/Image%7EAfib_ecg.jpg_8645.html" class="internal" title="Ecg of atrial fibrillation (top) and sinus rhythm (bottom)"><img src="../../../upload/shared/thumb/6/64/Afib_ecg.jpg/400px-Afib_ecg.jpg" alt="Ecg of atrial fibrillation (top) and sinus rhythm (bottom)" width="400" height="161" longdesc="../../../a/f/i/Image%7EAfib_ecg.jpg_8645.html" class="thumbimage" /></a>
<div class="thumbcaption">
<div class="magnify" style="float:right"><a href="../../../a/f/i/Image%7EAfib_ecg.jpg_8645.html" class="internal" title="Enlarge"><img src="../../../skins/common/images/magnify-clip.png" width="15" height="11" alt="" /></a></div>
Ecg of atrial fibrillation (top) and sinus rhythm (bottom)</div>
</div>
</div>
<p>Atrial fibrillation is diagnosed on an <a href="../../../e/l/e/Electrocardiogram.html" title="Electrocardiogram">electrocardiogram</a>, an investigation performed routinely whenever irregular heart beat is suspected. Characteristic findings are (a "rhythm strip" of lead II is shown):</p>
<ul>
<li>absence of P waves</li>
<li>unorganized electrical activity in their place</li>
<li>irregularity of R-R interval due to irregular conduction of impulses to the ventricles</li>
</ul>
<p>If paroxysmal AF is suspected, episodes may be documented with the use of <a href="../../../h/o/l/Holter_monitor.html" title="Holter monitor">Holter monitoring</a> (continuous ECG recording for 24 hours or longer).</p>
<p><a name="Other_investigations" id="Other_investigations"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Other investigations">edit</a>]</span> <span class="mw-headline">Other investigations</span></h3>
<p>While many cases of AF have no definite cause, it may be the result of various other problems (see below). Hence, <a href="../../../r/e/n/Renal_function.html" title="Renal function">renal function</a> and <a href="../../../e/l/e/Electrolyte.html" title="Electrolyte">electrolytes</a> are routinely determined, as well as <a href="../../../t/h/y/Thyroid-stimulating_hormone.html" title="Thyroid-stimulating hormone">thyroid-stimulating hormone</a> (commonly suppressed in <a href="../../../h/y/p/Hyperthyroidism.html" title="Hyperthyroidism">hyperthyroidism</a> and of relevance if <a href="../../../a/m/i/Amiodarone.html" title="Amiodarone">amiodarone</a> is administered for treatment) and a <a href="../../../c/o/m/Complete_blood_count.html" title="Complete blood count">blood count</a>. A <a href="../../../c/h/e/Chest_X-ray_6e61.html" title="Chest X-ray">chest X-ray</a> is generally performed. In acute-onset AF associated with <a href="../../../c/h/e/Chest_pain.html" title="Chest pain">chest pain</a>, <a href="../../../t/r/o/Troponin.html" title="Troponin">cardiac troponins</a> or other markers of damage to the heart muscle may be ordered. <a href="../../../c/o/a/Coagulation.html" title="Coagulation">Coagulation</a> studies (<a href="../../../i/n/t/International_normalized_ratio.html" title="International normalized ratio">INR</a>/aPTT) are usually performed, as <a href="../../../a/n/t/Anticoagulant.html" title="Anticoagulant">anticoagulant</a> medication may be commenced. A transesophageal <a href="../../../e/c/h/Echocardiogram.html" title="Echocardiogram">echocardiogram</a> may be indicated to identify any intracardiac thrombus. <a href="http://circ.ahajournals.org/cgi/content/full/104/17/2118?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fu#SEC7" class="external autonumber" title="http://circ.ahajournals.org/cgi/content/full/104/17/2118?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fu#SEC7" rel="nofollow">[1]</a></p>
<p><a name="Causes" id="Causes"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Causes">edit</a>]</span> <span class="mw-headline">Causes</span></h2>
<p>AF is linked to several cardiac causes, but may occur in otherwise normal hearts. Known associations include:</p>
<ul>
<li><a href="../../../c/a/r/Carbon_monoxide_poisoning.html" title="Carbon monoxide poisoning">Carbon monoxide poisoning</a></li>
<li><a href="../../../h/y/p/Hypertension.html" title="Hypertension">High blood pressure</a></li>
<li><a href="../../../m/i/t/Mitral_stenosis.html" title="Mitral stenosis">Mitral stenosis</a> (e.g. due to <a href="../../../r/h/e/Rheumatic_heart_disease.html" title="Rheumatic heart disease">rheumatic heart disease</a> or <a href="../../../m/i/t/Mitral_valve_prolapse.html" title="Mitral valve prolapse">mitral valve prolapse</a>)</li>
<li><a href="../../../m/i/t/Mitral_regurgitation.html" title="Mitral regurgitation">Mitral regurgitation</a></li>
<li><a href="../../../h/e/a/Heart_surgery.html" title="Heart surgery">Heart surgery</a></li>
<li><a href="../../../c/o/r/Coronary_artery_disease.html" title="Coronary artery disease">Coronary artery disease</a></li>
<li><a href="../../../h/y/p/Hypertrophic_cardiomyopathy.html" title="Hypertrophic cardiomyopathy">Hypertrophic cardiomyopathy</a></li>
<li>Excessive <a href="../../../a/l/c/Alcoholic_beverage.html" title="Alcoholic beverage">alcohol</a> consumption ("<a href="../../../b/i/n/Binge_drinking.html" title="Binge drinking">binge drinking</a>" or "<a href="../../../h/o/l/Holiday_heart_syndrome.html" title="Holiday heart syndrome">holiday heart syndrome</a>")</li>
<li><a href="../../../h/y/p/Hyperthyroidism.html" title="Hyperthyroidism">Hyperthyroidism</a></li>
<li>Hyperstimulation of the <a href="../../../v/a/g/Vagus_nerve.html" title="Vagus nerve">vagus nerve</a>, usually by having large meals ("<a href="../../../b/i/n/Binge_eating.html" title="Binge eating">binge eating</a>")</li>
<li>Lung pathology (such as <a href="../../../p/n/e/Pneumonia.html" title="Pneumonia">pneumonia</a>, <a href="../../../l/u/n/Lung_cancer.html" title="Lung cancer">lung cancer</a>, <a href="../../../p/u/l/Pulmonary_embolism.html" title="Pulmonary embolism">pulmonary embolism</a>, <a href="../../../s/a/r/Sarcoidosis.html" title="Sarcoidosis">Sarcoidosis</a>)</li>
<li><a href="../../../p/e/r/Pericarditis.html" title="Pericarditis">Pericarditis</a></li>
<li>Intense emotional turmoil</li>
<li>Congenital heart disease</li>
</ul>
<p><a name="Pathophysiology" id="Pathophysiology"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Pathophysiology">edit</a>]</span> <span class="mw-headline">Pathophysiology</span></h2>
<table border="1" style="border-collapse:collapse" cellpadding="3" align="center">
<tr>
<td colspan="3" align="center" bgcolor="#ABCDEF">Conduction</td>
</tr>
<tr>
<td><small>Sinus rhythm</small>
<div class="floatnone"><span><a href="../../../h/e/a/Image%7EHeart_conduct_sinus.gif_447d.html" class="image" title=""><img src="../../../upload/shared/c/c3/Heart_conduct_sinus.gif" alt="" width="230" height="217" longdesc="../../../h/e/a/Image%7EHeart_conduct_sinus.gif_447d.html" /></a></span></div>
</td>
<td><small>Atrial fibrillation</small>
<div class="floatnone"><span><a href="../../../h/e/a/Image%7EHeart_conduct_atrialfib.gif_f6ae.html" class="image" title=""><img src="../../../upload/shared/4/44/Heart_conduct_atrialfib.gif" alt="" width="230" height="217" longdesc="../../../h/e/a/Image%7EHeart_conduct_atrialfib.gif_f6ae.html" /></a></span></div>
</td>
</tr>
</table>
<p>The normal <a href="../../../e/l/e/Electrical_conduction_system_of_the_heart.html" title="Electrical conduction system of the heart">electrical conduction system of the heart</a> allows the impulse that is generated by the <a href="../../../s/i/n/Sinoatrial_node.html" title="Sinoatrial node">sinoatrial node</a> (SA node) of the heart to be propagated to and stimulate the <a href="../../../m/y/o/Myocardium.html" title="Myocardium">myocardium</a> (muscle of the heart). When the myocardium is stimulated, it contracts. It is the ordered stimulation of the myocardium that allows efficient contraction of the heart, thereby allowing blood to be pumped to the body.</p>
<p>In atrial fibrillation, the regular impulses produced by the sinus node to provide rhythmic contraction of the heart are overwhelmed by the rapid randomly generated electrical discharges produced by larger areas of atrial tissue. It can be distinguished from <a href="../../../a/t/r/Atrial_flutter.html" title="Atrial flutter">atrial flutter</a>, which is a more organized electrical circuit usually in the right atrium that produces characteristic saw toothed p-waves on the electrocardiogram.</p>
<p>Often, the rhythm produced is more rapid than normal, but the difficulty is in obtaining control of the heart rate both at rest and with exercise. Good rate control will usually require two drugs, and can only be checked by observing heart rate response to exercise.</p>
<p>An organized electrical impulse in the atrium produces atrial contraction; the lack of such an impulse, as in atrial fibrillation, produces stagnant blood flow, especially in the atrial appendage and predisposes to clotting. The dislodgement of a clot from the atrium results in an embolus, and the damage produced is related to where the circulation takes it. An embolus to the brain produces the most feared complication of atrial fibrillation, stroke, while an embolus may also lodge in the mesenteric circulation (the circulation supplying the abdominal organs) or digit, producing organ-specific damage.</p>
<p><a name="Treatment" id="Treatment"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Treatment">edit</a>]</span> <span class="mw-headline">Treatment</span></h2>
<p>The main goals of treatment of atrial fibrillation are to prevent temporary circulatory instability and to prevent <a href="../../../s/t/r/Stroke.html" title="Stroke">stroke</a>. Rate and rhythm control are principally used to achieve the former, while <a href="../../../a/n/t/Anticoagulation.html" title="Anticoagulation">anticoagulation</a> may be required to decrease the risk of the latter.<sup id="_ref-4" class="reference"><a href="#_note-4" title="">[5]</a></sup> The primary factors determining atrial fibrillation treatment are duration and evidence of hemodynamic instability. <a href="../../../c/a/r/Cardioversion.html" title="Cardioversion">Cardioversion</a> is indicated with new onset AF (for less than 48 hours) and with hemodynamic instability. If rate and rhythm control can not be maintained by medication or cardioversion, ablation by a trained Electrophysiologist may be suggested.</p>
<p>AF can cause disabling and annoying symptoms. <a href="../../../p/a/l/Palpitations.html" title="Palpitations">Palpitations</a>, <a href="../../../a/n/g/Angina.html" title="Angina">angina</a>, lassitude (weariness), and decreased exercise tolerance are related to rapid heart rate and inefficient cardiac output caused by AF. There are two ways to approach these symptoms: rate control and rhythm control. <i>Rate control</i> treatments seek to reduce the heart rate to normal, usually 60 to 100 beats per minute. <i>Rhythm control</i> seeks to restore the normal heart rhythm, called normal sinus rhythm. Studies suggest that rhythm control is mainly a concern in newly diagnosed AF, while rate control is more important in the chronic phase. Rate control with anticoagulation is as effective a treatment as rhythm control in long term mortality studies, the AFFIRM Trial (Wyse et al., 2002).</p>
<p>AF with a persistent rapid rate can cause a form of <a href="../../../h/e/a/Heart_failure.html" title="Heart failure">heart failure</a> called <a href="../../../t/a/c/Tachycardia_induced_cardiomyopathy.html" title="Tachycardia induced cardiomyopathy">tachycardia induced cardiomyopathy</a>. This can significantly increase mortality and morbidity. The early treatment of AF through either rate-control or rhythm-control can prevent this condition and thereby improve mortality and morbidity.</p>
<p><a name="Rate_control" id="Rate_control"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Rate control">edit</a>]</span> <span class="mw-headline">Rate control</span></h3>
<p>Rate control methods include:</p>
<ul>
<li><a href="../../../b/e/t/Beta_blockers.html" title="Beta blockers">Beta blockers</a> (e.g. <a href="../../../m/e/t/Metoprolol.html" title="Metoprolol">metoprolol</a>)</li>
<li><a href="../../../c/a/r/Cardiac_glycosides.html" title="Cardiac glycosides">Cardiac glycosides</a> (i.e. <a href="../../../d/i/g/Digoxin.html" title="Digoxin">digoxin</a>)</li>
<li><a href="../../../c/a/l/Calcium_channel_blocker.html" title="Calcium channel blocker">Calcium channel blockers</a> (i.e. <a href="../../../d/i/l/Diltiazem.html" title="Diltiazem">diltiazem</a> or <a href="../../../v/e/r/Verapamil.html" title="Verapamil">verapamil</a>)</li>
</ul>
<p>These medications work by slowing the generation of impulses from the atria and the conduction of those impulse from the atria to the ventricles.</p>
<p>In refractory cases where none of the above drugs are sufficient, a variety of other antiarrhythmic drugs, most commonly including <a href="../../../q/u/i/Quinidine.html" title="Quinidine">quinidine</a>, <a href="../../../f/l/e/Flecainide.html" title="Flecainide">flecainide</a>, <a href="../../../p/r/o/Propafenone.html" title="Propafenone">propafenone</a>, <a href="../../../d/i/s/Disopyramide.html" title="Disopyramide">disopyramide</a>, <a href="../../../s/o/t/Sotalol.html" title="Sotalol">sotalol</a>, or <a href="../../../a/m/i/Amiodarone.html" title="Amiodarone">amiodarone</a> may be used. Of these, only propafenone, sotalol, and amiodarone (which possess some beta blocking activity) control the ventricular rate; the others may maintain sinus rhythm, but may actually increase the ventricular rate. Many of these drugs are less frequently used today than in the past. All (with the possible exception of amiodarone) increase the risk of ventricular tachycardia, which can be fatal. In symptomatic patients with normal heart function, however, the small increase in risk is usually felt to be acceptable. In the presence of heart failure, the only antiarrhythmic drugs thought to be safe are amiodarone and dofetilide. In the United States, it should be noted that many of these agents are not approved by the <a href="../../../f/d/a/FDA_274c.html" title="FDA">FDA</a> for this use.</p>
<p>In emergencies, when circulatory collapse is imminent due to uncontrolled <a href="../../../t/a/c/Tachycardia.html" title="Tachycardia">tachycardia</a>, immediate <a href="../../../c/a/r/Cardioversion.html" title="Cardioversion">cardioversion</a> may be indicated. <a href="http://circ.ahajournals.org/cgi/content/full/104/17/2118?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fu#SEC8" class="external autonumber" title="http://circ.ahajournals.org/cgi/content/full/104/17/2118?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fu#SEC8" rel="nofollow">[2]</a></p>
<p><a name="Rhythm_control" id="Rhythm_control"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Rhythm control">edit</a>]</span> <span class="mw-headline">Rhythm control</span></h3>
<p>Rhythm control methods include electrical and chemical cardioversion:</p>
<ul>
<li><i><a href="../../../c/a/r/Cardioversion.html" title="Cardioversion">Electrical cardioversion</a></i> involves the restoration of normal heart rhythm through the application of a DC electrical shock.</li>
<li><i><a href="../../../c/a/r/Cardioversion.html" title="Cardioversion">Chemical cardioversion</a></i> is performed with drugs, such as <a href="../../../a/m/i/Amiodarone.html" title="Amiodarone">amiodarone</a>, <a href="../../../p/r/o/Procainamide.html" title="Procainamide">procainamide</a>, <a href="../../../i/b/u/Ibutilide.html" title="Ibutilide">ibutilide</a>, <a href="../../../p/r/o/Propafenone.html" title="Propafenone">propafenone</a> or <a href="../../../f/l/e/Flecainide.html" title="Flecainide">flecainide</a>.</li>
</ul>
<p>The <a href="../../../a/n/t/Antiarrhythmic_agent.html" title="Antiarrhythmic agent">anti-arrhythmic medications</a> often used in either pharmacological cardioversion or in the prevention of relapse to AF alter the flux of ions in heart tissue, making them less excitable, setting the stage for spontaneous and durable cardioversion. These medications are often used in concert with electrical cardioversion. However, the AFFIRM study showed no difference in risk of stroke in patients who have converted to a normal rhythm with anti-arrhythmic treatment, compared to those who have only rate control.<sup id="_ref-5" class="reference"><a href="#_note-5" title="">[6]</a></sup></p>
<p>The main risk of cardioversion is systemic embolization of a <a href="../../../b/l/o/Blood_clot.html" title="Blood clot">blood clot</a> from the previously fibrillating left atrium. Cardioversion should not be performed without adequate anticoagulation in patients with more than 48 hours of atrial fibrillation. Cardioversion may be performed in instances of AF lasting more than 48 hours if a <a href="../../../t/r/a/Transesophogeal_echocardiogram.html" title="Transesophogeal echocardiogram">transesophogeal echocardiogram</a> (TEE) demonstrates no evidence of clot within the heart.</p>
<p>Whichever method of cardioversion is used, approximately 50% of patient <a href="../../../r/e/l/Relapse.html" title="Relapse">relapse</a> within one year, although the continued daily use of oral antiarrhythmic drugs may extend this period. The key risk factor for relapse is duration of AF, although other risk factors that have been identified include the presence of structural heart disease, and increasing age.</p>
<p><a name="Radiofrequency_ablation" id="Radiofrequency_ablation"></a></p>
<h4><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Radiofrequency ablation">edit</a>]</span> <span class="mw-headline">Radiofrequency ablation</span></h4>
<p>In patients with AF where rate control drugs are ineffective and it is not possible to restore sinus rhythm using cardioversion, non-pharmacological alternatives are available. For example, to control rate it is possible to destroy the bundle of cells connecting the upper and lower chambers of the heart - the atrioventricular node - which regulates heart rate, and to implant a pacemaker instead. A more complex technique, which avoids the need for a pacemaker, involves ablating groups of cells near the pulmonary veins where atrial fibrillation is thought to originate, or creating more extensive lesions in an attempt to prevent atrial fibrillation from establishing itself.<a href="http://circ.ahajournals.org/cgi/content/full/104/17/2118?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fu#SEC8" class="external autonumber" title="http://circ.ahajournals.org/cgi/content/full/104/17/2118?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fu#SEC8" rel="nofollow">[3]</a></p>
<p>Ablation is a newer technique and has shown some promise for cases of recurrent AF that are unresponsive to conventional treatments. <a href="../../../r/a/d/Radiofrequency_ablation.html" title="Radiofrequency ablation">Radiofrequency ablation</a> (RFA) uses radiofrequency energy to destroy abnormal electrical pathways in heart tissue. The energy emitting probe (<a href="../../../e/l/e/Electrode.html" title="Electrode">electrode</a>) is placed into the heart through a <a href="../../../c/a/t/Catheter.html" title="Catheter">catheter</a> inserted into veins in the groin or neck. Electrodes that can detect electrical activity from inside the heart are also inserted, and the electrophysiologist uses these to "map" an area of the heart in order to locate the abnormal electrical activity before eliminating the responsible tissue.</p>
<p>Most AF ablations consist of isolating the pulmonary veins (PV), which are located on the posterior wall of the left atrium. All veins from the body (including neck and groin) lead to the right atrium. In order to get to the left atrium the catheters must get across the atrial septum. This is done by peircing a small hole in the septal wall. This is called a transeptal approach. Once in the left atrium, the physician may perform Wide Area Circumferencial Ablation (WACA) to electrically isolate the PVs from the left atrium.</p>
<p>Some more recent approaches to ablating AF is to target sites that are particularly disorganized in both atria as well as in the coronary sinus (CS). These sites are termed complex fractionated atrial electrogram (CFAE) sites<sup id="_ref-6" class="reference"><a href="#_note-6" title="">[7]</a></sup>. It is believed by some that the CFAE sites are the cause of AF, or a combination of the PVs and CFAE sites are to blame. New techniques include the use of <a href="../../../c/r/y/Cryoablation.html" title="Cryoablation">cryoablation</a> (tissue freezing using a coolant which flows through the catheter), and microwave ablation, where tissue is ablated by the microwave energy "cooking" the adjacent tissue.</p>
<p>This is an area of active research, especially with respect to the RF ablation technique and emphasis on isolating the pulmonary veins that enter into the left atrium. The main problem in 2006 is that the procedure is only 70-80% effective at best -- and causes stroke in about 1% of patients.</p>
<p><a name="Cox_maze_Procedure" id="Cox_maze_Procedure"></a></p>
<h4><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Cox maze Procedure">edit</a>]</span> <span class="mw-headline">Cox maze Procedure</span></h4>
<p>James Cox, MD, and associates developed the Cox maze procedure, an open-heart surgical procedure intended to eliminate atrial fibrillation, and performed the first one in 1987. "Maze" refers to the series of incisions made in the atria (upper chambers of the heart), which are arranged in a maze-like pattern. The intention was to eliminate AF by using incisional scars to block abnormal electrical circuits (atrial macroreentry) that AF requires. This procedure required an extensive series of endocardial (from the inside of the heart) incisions through both atria, a median sternotomy (vertical incision through the breastbone) and cardiopulmonary bypass (heart-lung machine). A series of improvements were made, culminating in 1992 in the Cox maze III procedure, which is now considered to be the "gold standard” for effective surgical cure of AF. The Cox maze III is sometimes referred to as the “traditional maze”, the “cut and sew maze”, or simply the "maze".</p>
<p><a name="Minimaze_surgical_procedures" id="Minimaze_surgical_procedures"></a></p>
<h4><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Minimaze surgical procedures">edit</a>]</span> <span class="mw-headline">Minimaze surgical procedures</span></h4>
<p><a href="../../../m/i/n/Minimaze.html" title="Minimaze">Minimaze</a> surgery is minimally invasive cardiac surgery intended to cure atrial fibrillation. <a href="../../../m/i/n/Minimaze.html" title="Minimaze">Minimaze</a> refers to "mini" versions of the original maze procedure. These procedures are less invasive than the Cox maze procedure and do not require a median sternotomy (vertical incision in the breastbone) or cardiopulmonary bypass (heart-lung machine). These procedures use microwave, radiofrequency, or acoustic energy to ablate atrial tissue near the pulmonary veins.</p>
<p><a name="Anticoagulation" id="Anticoagulation"></a></p>
<h3><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Anticoagulation">edit</a>]</span> <span class="mw-headline">Anticoagulation</span></h3>
<p>In confirmed AF, <a href="../../../a/n/t/Anticoagulant.html" title="Anticoagulant">anticoagulant</a> treatment is a crucial way to prevent <a href="../../../c/e/r/Cerebrovascular_accident.html" title="Cerebrovascular accident">stroke</a>. Treatment of AF patients over age 60, who also have one or more of: previous strokes (or warning strokes), hypertension (high blood pressure), diabetes, or congestive heart failure, with <a href="../../../w/a/r/Warfarin.html" title="Warfarin">warfarin</a> (also known as Coumadin® or Marevan®) results in a 60 to 70 percent reduction in the subsequent risk of stroke. Patients under age 65 who have any structural heart disease (i.e. valvular heart disease, <a href="../../../e/j/e/Ejection_fraction.html" title="Ejection fraction">ejection fraction</a> &lt;= 35%, history of <a href="../../../m/y/o/Myocardial_infarction.html" title="Myocardial infarction">heart attack</a>) may also benefit from warfarin.</p>
<p>The use of warfarin is associated with a delayed clinical effect. It typically takes three to five days to achieve a demonstrable anticoagulant effect. Hence, if an immediate anticoagulant effect is required, physicians could use <a href="../../../h/e/p/Heparin.html" title="Heparin">heparin</a> or other heparinoids such as <a href="../../../e/n/o/Enoxaparin.html" title="Enoxaparin">enoxaparin</a> to provide early anticoagulation. In practice, urgent anticoagulation is seldom indicated. Even in the setting of stroke complicating atrial fibrillation, clinical trial results do not support the routine use of immediate anticoagulation.</p>
<p>Patients under age 65 who do not have structural heart disease (i.e. with LAF) do not require warfarin, and can be treated with <a href="../../../a/s/p/Aspirin.html" title="Aspirin">aspirin</a> <sup id="_ref-7" class="reference"><a href="#_note-7" title="">[8]</a></sup> or <a href="../../../c/l/o/Clopidogrel.html" title="Clopidogrel">clopidogrel</a>. There is evidence that aspirin and clopidogrel are effective when used together, but the combination is still inferior to warfarin.<sup id="_ref-8" class="reference"><a href="#_note-8" title="">[9]</a></sup> The <a href="../../../a/s/_/As_of_2005.html" title="As of 2005">new</a> anticoagulant <a href="../../../x/i/m/Ximelagatran.html" title="Ximelagatran">ximelagatran</a> has been shown to prevent stroke with equal efficacy as warfarin, without the difficult monitoring process associated with warfarin and with possibly fewer adverse haemorrhagic events. Unfortunately, ximegalatran and other similar anticoagulant drugs (commonly referred to as direct thrombin inhibitors), have yet to be widely licensed. License applications for ximelegatran (made by AstraZeneca) have been rejected by both American and European licensing authorities, and its evaluation has been suspended in the UK. This is primarily due to concerns over possible liver toxicity.</p>
<p>Determining who should and should not receive anti-coagulation with warfarin is not easy. The <a href="../../../c/h/a/CHADS2_f64c.html" title="CHADS2">CHADS2</a> score is the best validated method of determining risk of stroke (and therefore who should be anticoagulated). The UK NICE guidelines have instead opted for an algorithm approach. The underlying problem is that if a patient has a yearly risk of stroke that is less than 2%, then the risks associated with taking warfarin outweigh the risk of getting a stroke.<sup id="_ref-9" class="reference"><a href="#_note-9" title="">[10]</a></sup><sup id="_ref-10" class="reference"><a href="#_note-10" title="">[11]</a></sup></p>
<p>It is worth noting that patient with AF who are being rhythm controlled are not treated any differently from patients with permanent AF when it comes to determining anticoagulation.</p>
<p><a name="Prognosis" id="Prognosis"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Prognosis">edit</a>]</span> <span class="mw-headline">Prognosis</span></h2>
<p>Atrial fibrillation can usually be controlled with treatment. The natural tendency of atrial fibrillation, however, is to become a chronic condition. Chronic AF leads to an increased risk of death. Patients with atrial fibrillation are at significantly increased chance of stroke (about 2 to 7 times the regular population)</p>
<p><a name="Epidemiology" id="Epidemiology"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Epidemiology">edit</a>]</span> <span class="mw-headline">Epidemiology</span></h2>
<p>Atrial fibrillation is common among older adults. In developed countries, the number of patients with atrial fibrillation is likely to increase during the next 50 years, due to the growing proportion of elderly individuals.<sup id="_ref-11" class="reference"><a href="#_note-11" title="">[12]</a></sup></p>
<p><a name="History" id="History"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: History">edit</a>]</span> <span class="mw-headline">History</span></h2>
<p>Because the diagnosis of atrial fibrillation requires measurement of the electrical activity of the heart, atrial fibrillation was not truly described until 1874, when <a href="../../../e/d/m/Edm%C3%A9_F%C3%A9lix_Alfred_Vulpian_dfa1.html" title="Edmé Félix Alfred Vulpian">Edmé Félix Alfred Vulpian</a> observed the irregular atrial electrical behavior that he termed <i>"fremissement fibrillaire"</i> in dog hearts.<sup id="_ref-12" class="reference"><a href="#_note-12" title="">[13]</a></sup> However, the irregular pulse and its association with disease have been recognized since antiquity. Direct visualization of cardiac fibrillation was first described in 1628 by <a href="../../../w/i/l/William_Harvey_b040.html" title="William Harvey">William Harvey</a> in dying animals. In the mid-eighteenth century, Jean Baptiste de Sénac made note of dilated, irritated atria in people with <a href="../../../m/i/t/Mitral_stenosis.html" title="Mitral stenosis">mitral stenosis</a>.<sup id="_ref-13" class="reference"><a href="#_note-13" title="">[14]</a></sup> The irregular pulse associated with AF was first recorded in 1876 by <a href="../../../c/a/r/Carl_Nothnagel_8bbf.html" title="Carl Nothnagel">Carl Wilhelm Hermann Nothnagel</a> and termed <i>"delirium cordis"</i> stating, "In this form of arrhythmia the heartbeats follow each other in complete irregularity. At the same time, the height and tension of the individual pulse waves are continuously changing."<sup id="_ref-14" class="reference"><a href="#_note-14" title="">[15]</a></sup> Correlation of delirium cordis with the loss of atrial contraction as reflected in the loss of <i>a waves</i> in the <a href="../../../j/u/g/Jugular_venous_pressure.html" title="Jugular venous pressure">jugular venous pulse</a> was made by Sir James MacKenzie in 1904.<sup id="_ref-15" class="reference"><a href="#_note-15" title="">[16]</a></sup> <a href="../../../w/i/l/Willem_Einthoven_a021.html" title="Willem Einthoven">Willem Einthoven</a> published the first <a href="../../../e/l/e/Electrocardiogram.html" title="Electrocardiogram">electrocardiogram</a> showing AF in 1906.<sup id="_ref-16" class="reference"><a href="#_note-16" title="">[17]</a></sup> The connection between the anatomic and electrical manifestations of AF and the irregular pulse of delirium cordis was made in 1909 by Carl Julius Rothberger, Heinrich Winterberg, and Sir Thomas Lewis.<sup id="_ref-17" class="reference"><a href="#_note-17" title="">[18]</a></sup><sup id="_ref-18" class="reference"><a href="#_note-18" title="">[19]</a></sup><sup id="_ref-19" class="reference"><a href="#_note-19" title="">[20]</a></sup></p>
<p><a name="See_also" id="See_also"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: See also">edit</a>]</span> <span class="mw-headline">See also</span></h2>
<ul>
<li><a href="../../../a/t/r/Atrial_flutter.html" title="Atrial flutter">Atrial flutter</a></li>
<li><a href="../../../a/s/h/Ashman_phenomenon.html" title="Ashman phenomenon">Ashman phenomenon</a></li>
</ul>
<p><a name="Notes_and_references" id="Notes_and_references"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: Notes and references">edit</a>]</span> <span class="mw-headline">Notes and references</span></h2>
<ol class="references">
<li id="_note-0"><b><a href="#_ref-0" title="">^</a></b> <a href="http://circ.ahajournals.org/cgi/content/full/104/17/2118?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fu#SEC3" class="external text" title="http://circ.ahajournals.org/cgi/content/full/104/17/2118?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fu#SEC3" rel="nofollow">AHA Consensus for classification</a></li>
<li id="_note-1"><b><a href="#_ref-1" title="">^</a></b> <cite style="font-style:normal">Levy S (1998). "Epidemiology and classification of atrial fibrillation". <i>J Cardiovasc Electrophysiol</i> <b>9</b> (8 Suppl): S78-82.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Epidemiology+and+classification+of+atrial+fibrillation&amp;rft.title=J+Cardiovasc+Electrophysiol&amp;rft.jtitle=J+Cardiovasc+Electrophysiol&amp;rft.date=1998&amp;rft.volume=9&amp;rft.issue=8+Suppl&amp;rft.au=Levy+S&amp;rft.pages=S78-82">&#160;</span> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9727680" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9727680">PMID 9727680</a></li>
<li id="_note-2"><b><a href="#_ref-2" title="">^</a></b> <cite style="font-style:normal">Levy S (2000). "Classification system of atrial fibrillation". <i>Curr Opin Cardiol</i> <b>15</b> (1): 54-7.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Classification+system+of+atrial+fibrillation&amp;rft.title=Curr+Opin+Cardiol&amp;rft.jtitle=Curr+Opin+Cardiol&amp;rft.date=2000&amp;rft.volume=15&amp;rft.issue=1&amp;rft.au=Levy+S&amp;rft.pages=54-7">&#160;</span> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10666661" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10666661">PMID 10666661</a></li>
<li id="_note-3"><b><a href="#_ref-3" title="">^</a></b> <a href="http://circ.ahajournals.org/cgi/content/full/104/17/2118?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fu#SEC3" class="external text" title="http://circ.ahajournals.org/cgi/content/full/104/17/2118?maxtoshow=&amp;HITS=10&amp;hits=10&amp;RESULTFORMAT=&amp;fu#SEC3" rel="nofollow">ACC/AHA/ESC Guidelines for the Management of Patients With Atrial Fibrillation</a></li>
<li id="_note-4"><b><a href="#_ref-4" title="">^</a></b> <cite style="font-style:normal">Prystowsky EN (2000). "Management of atrial fibrillation: therapeutic options and clinical decisions". <i>Am J Cardiol</i> <b>85</b> (10A): 3D-11D.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Management+of+atrial+fibrillation%3A+therapeutic+options+and+clinical+decisions&amp;rft.title=Am+J+Cardiol&amp;rft.jtitle=Am+J+Cardiol&amp;rft.date=2000&amp;rft.volume=85&amp;rft.issue=10A&amp;rft.au=Prystowsky+EN&amp;rft.pages=3D-11D">&#160;</span> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10822035" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=10822035">PMID 10822035</a></li>
<li id="_note-5"><b><a href="#_ref-5" title="">^</a></b> <cite style="font-style:normal">Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD (2002). "A comparison of rate control and rhythm control in patients with atrial fibrillation". <i>N Engl J Med</i> <b>347</b> (23): 1825-33.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=A+comparison+of+rate+control+and+rhythm+control+in+patients+with+atrial+fibrillation&amp;rft.title=N+Engl+J+Med&amp;rft.jtitle=N+Engl+J+Med&amp;rft.date=2002&amp;rft.volume=347&amp;rft.issue=23&amp;rft.au=Wyse+DG%2C+Waldo+AL%2C+DiMarco+JP%2C+Domanski+MJ%2C+Rosenberg+Y%2C+Schron+EB%2C+Kellen+JC%2C+Greene+HL%2C+Mickel+MC%2C+Dalquist+JE%2C+Corley+SD&amp;rft.pages=1825-33">&#160;</span> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12466506" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=12466506">PMID 12466506</a></li>
<li id="_note-6"><b><a href="#_ref-6" title="">^</a></b> <cite style="font-style:normal">Nademanee K, McKenzie J, Kosar E, Schwab M, Sunsaneewitayakul B, Vasavakul T, Khunnawat C, Ngarmukos T. (2004). "A new approach for catheter ablation of atrial fibrillation: mapping of the electrophysiologic substrate". <i>J Am Coll Cardiol</i> <b>43</b> (11): 2044-53.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=A+new+approach+for+catheter+ablation+of+atrial+fibrillation%3A+mapping+of+the+electrophysiologic+substrate&amp;rft.title=J+Am+Coll+Cardiol&amp;rft.jtitle=J+Am+Coll+Cardiol&amp;rft.date=2004&amp;rft.volume=43&amp;rft.issue=11&amp;rft.au=Nademanee+K%2C+McKenzie+J%2C+Kosar+E%2C+Schwab+M%2C+Sunsaneewitayakul+B%2C+Vasavakul+T%2C+Khunnawat+C%2C+Ngarmukos+T.&amp;rft.pages=2044-53">&#160;</span> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15172410" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15172410">PMID 15172410</a></li>
<li id="_note-7"><b><a href="#_ref-7" title="">^</a></b> <cite style="font-style:normal">Fuster V, Ryden LE, Asinger RW, Cannom DS, Crijns HJ, Frye RL, Halperin JL, Kay GN, Klein WW, Levy S, McNamara RL, Prystowsky EN, Wann LS, Wyse DG, Gibbons RJ, Antman EM, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Russell RO, Smith SC, Klein WW, Alonso-Garcia A, Blomstrom-Lundqvist C, De Backer G, Flather M, Hradec J, Oto A, Parkhomenko A, Silber S, Torbicki A (2001). "ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology". <i>J Am Coll Cardiol</i> <b>38</b> (4): 1231-66.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=ACC%2FAHA%2FESC+guidelines+for+the+management+of+patients+with+atrial+fibrillation%3A+executive+summary.+A+Report+of+the+American+College+of+Cardiology%2F+American+Heart+Association+Task+Force+on+Practice+Guidelines+and+the+European+Society+of+Cardiology+Committee+for+Practice+Guidelines+and+Policy+Conferences+%28Committee+to+Develop+Guidelines+for+the+Management+of+Patients+With+Atrial+Fibrillation%29%3A+developed+in+Collaboration+With+the+North+American+Society+of+Pacing+and+Electrophysiology&amp;rft.title=J+Am+Coll+Cardiol&amp;rft.jtitle=J+Am+Coll+Cardiol&amp;rft.date=2001&amp;rft.volume=38&amp;rft.issue=4&amp;rft.au=Fuster+V%2C+Ryden+LE%2C+Asinger+RW%2C+Cannom+DS%2C+Crijns+HJ%2C+Frye+RL%2C+Halperin+JL%2C+Kay+GN%2C+Klein+WW%2C+Levy+S%2C+McNamara+RL%2C+Prystowsky+EN%2C+Wann+LS%2C+Wyse+DG%2C+Gibbons+RJ%2C+Antman+EM%2C+Alpert+JS%2C+Faxon+DP%2C+Fuster+V%2C+Gregoratos+G%2C+Hiratzka+LF%2C+Jacobs+AK%2C+Russell+RO%2C+Smith+SC%2C+Klein+WW%2C+Alonso-Garcia+A%2C+Blomstrom-Lundqvist+C%2C+De+Backer+G%2C+Flather+M%2C+Hradec+J%2C+Oto+A%2C+Parkhomenko+A%2C+Silber+S%2C+Torbicki+A&amp;rft.pages=1231-66">&#160;</span> <a href="http://www.acc.org/clinical/guidelines/atrial_fib/af_index.htm" class="external text" title="http://www.acc.org/clinical/guidelines/atrial_fib/af_index.htm" rel="nofollow">ACC/AHA/ESC Fulltext</a> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11583910" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11583910">PMID 11583910</a></li>
<li id="_note-8"><b><a href="#_ref-8" title="">^</a></b> <cite style="font-style:normal">ACTIVE investigators. "Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE W): a randomised controlled trial". <i>Lancet</i> <b>367</b>: 1903–12.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Clopidogrel+plus+aspirin+versus+oral+anticoagulation+for+atrial+fibrillation+in+the+atrial+fibrillation+clopidogrel+trial+with+irbesartan+for+prevention+of+vascular+events+%28ACTIVE+W%29%3A+a+randomised+controlled+trial&amp;rft.title=Lancet&amp;rft.jtitle=Lancet&amp;rft.volume=367&amp;rft.au=ACTIVE+investigators&amp;rft.pages=1903%26ndash%3B12">&#160;</span></li>
<li id="_note-9"><b><a href="#_ref-9" title="">^</a></b> <cite style="font-style:normal">van Walraven C, Hart RG, Singer DE, <i>et al.</i> (2002). "<a href="http://jama.ama-assn.org/cgi/content/abstract/288/19/2441?ijkey=ed594945b7ea327312fef69b7bde130df41eb012&amp;keytype2=tf_ipsecsha" class="external text" title="http://jama.ama-assn.org/cgi/content/abstract/288/19/2441?ijkey=ed594945b7ea327312fef69b7bde130df41eb012&amp;keytype2=tf_ipsecsha" rel="nofollow">Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis</a>". <i>JAMA</i> <b>288</b> (19): 2441–48.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Oral+anticoagulants+vs+aspirin+in+nonvalvular+atrial+fibrillation%3A+an+individual+patient+meta-analysis&amp;rft.title=JAMA&amp;rft.jtitle=JAMA&amp;rft.date=2002&amp;rft.volume=288&amp;rft.issue=19&amp;rft.au=van+Walraven+C%2C+Hart+RG%2C+Singer+DE%2C+%27%27et+al.%27%27&amp;rft.pages=2441%26ndash%3B48&amp;rft_id=http%3A%2F%2Fjama.ama-assn.org%2Fcgi%2Fcontent%2Fabstract%2F288%2F19%2F2441%3Fijkey%3Ded594945b7ea327312fef69b7bde130df41eb012%26keytype2%3Dtf_ipsecsha">&#160;</span></li>
<li id="_note-10"><b><a href="#_ref-10" title="">^</a></b> <cite style="font-style:normal">Gage BF, Cardinalli AB, Owens D. (1998). "<a href="http://stroke.ahajournals.org/cgi/content/abstract/29/6/1083?ijkey=f0c55903eccf70a1e526d73dc47b4e672bb31858&amp;keytype2=tf_ipsecsha" class="external text" title="http://stroke.ahajournals.org/cgi/content/abstract/29/6/1083?ijkey=f0c55903eccf70a1e526d73dc47b4e672bb31858&amp;keytype2=tf_ipsecsha" rel="nofollow">Cost-effectiveness of preference-based antithrombotic therapy for patients with nonvalvular atrial fibrillation</a>". <i>Stroke</i> <b>29</b>: 1083–91.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Cost-effectiveness+of+preference-based+antithrombotic+therapy+for+patients+with+nonvalvular+atrial+fibrillation&amp;rft.title=Stroke&amp;rft.jtitle=Stroke&amp;rft.date=1998&amp;rft.volume=29&amp;rft.au=Gage+BF%2C+Cardinalli+AB%2C+Owens+D.&amp;rft.pages=1083%26ndash%3B91&amp;rft_id=http%3A%2F%2Fstroke.ahajournals.org%2Fcgi%2Fcontent%2Fabstract%2F29%2F6%2F1083%3Fijkey%3Df0c55903eccf70a1e526d73dc47b4e672bb31858%26keytype2%3Dtf_ipsecsha">&#160;</span></li>
<li id="_note-11"><b><a href="#_ref-11" title="">^</a></b> <cite style="font-style:normal">Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE (2001). "Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study". <i>JAMA</i> <b>285</b> (18): 2370-5.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Prevalence+of+diagnosed+atrial+fibrillation+in+adults%3A+national+implications+for+rhythm+management+and+stroke+prevention%3A+the+AnTicoagulation+and+Risk+Factors+in+Atrial+Fibrillation+%28ATRIA%29+Study&amp;rft.title=JAMA&amp;rft.jtitle=JAMA&amp;rft.date=2001&amp;rft.volume=285&amp;rft.issue=18&amp;rft.au=Go+AS%2C+Hylek+EM%2C+Phillips+KA%2C+Chang+Y%2C+Henault+LE%2C+Selby+JV%2C+Singer+DE&amp;rft.pages=2370-5">&#160;</span> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11343485" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=11343485">PMID 11343485</a></li>
<li id="_note-12"><b><a href="#_ref-12" title="">^</a></b> Vulpian A. <i>Note sur les effets de la faradisation directe des ventricules du coeur chez le chien.</i> Archives de Physiologie Normale et Pathologique. 1874; 6:975</li>
<li id="_note-13"><b><a href="#_ref-13" title="">^</a></b> McMichael J. <i>History of atrial fibrillation 1628-1819 Harvey-de Senac-Laennec.</i> Br Heart J. 1982; 48:193-7 <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7049202" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7049202">PMID 7049202</a></li>
<li id="_note-14"><b><a href="#_ref-14" title="">^</a></b> Nothnagel H. <i>Ueber arythmische Herzthatigkeit.</i> Deutsches Archiv fur Klinische Medizin. 1876; 17:190-220</li>
<li id="_note-15"><b><a href="#_ref-15" title="">^</a></b> MacKenzie J. <i>The inception of the rhythm of the heart by the ventricle.</i> Br Med J. 1904; 1:529-36</li>
<li id="_note-16"><b><a href="#_ref-16" title="">^</a></b> Einthoven W. <i>Le telecardiogramme.</i> Archives Internationales de Physiologie. 1906; 4:132-64</li>
<li id="_note-17"><b><a href="#_ref-17" title="">^</a></b> Rothberger CJ, Winterberg H. <i>Vorhofflimmern und Arhythmia perpetua.</i> Wiener Klinische Wochenschrift. 1909; 22:839-44</li>
<li id="_note-18"><b><a href="#_ref-18" title="">^</a></b> Lewis T. <i>Auricular fibrillation: a common clinical condition.</i> Br Med J. 1909; 2:1528</li>
<li id="_note-19"><b><a href="#_ref-19" title="">^</a></b> Flegel KM.<i>From delirium cordis to atrial fibrillation: historical development of a disease concept.</i> Ann Intern Med. 1995 Jun 1;122(11):867-73. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7741373" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=7741373">PMID 7741373</a></li>
</ol>
<ul>
<li><cite style="font-style:normal">Levy S, Breithardt G, Campbell RW, Camm AJ, Daubert JC, Allessie M, Aliot E, Capucci A, Cosio F, Crijns H, Jordaens L, Hauer RN, Lombardi F, Luderitz B (1998). "Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology". <i>Eur Heart J</i> <b>19</b> (9): 1294-320.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Atrial+fibrillation%3A+current+knowledge+and+recommendations+for+management.+Working+Group+on+Arrhythmias+of+the+European+Society+of+Cardiology&amp;rft.title=Eur+Heart+J&amp;rft.jtitle=Eur+Heart+J&amp;rft.date=1998&amp;rft.volume=19&amp;rft.issue=9&amp;rft.au=Levy+S%2C+Breithardt+G%2C+Campbell+RW%2C+Camm+AJ%2C+Daubert+JC%2C+Allessie+M%2C+Aliot+E%2C+Capucci+A%2C+Cosio+F%2C+Crijns+H%2C+Jordaens+L%2C+Hauer+RN%2C+Lombardi+F%2C+Luderitz+B&amp;rft.pages=1294-320">&#160;</span> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9792255" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=9792255">PMID 9792255</a></li>
<li><cite style="font-style:normal">Greenlee RT, Vidaillet H (2005). "Recent progress in the epidemiology of atrial fibrillation". <i>Curr Opin Cardiol</i> <b>20</b> (1): 7-14.</cite><span class="Z3988" title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.atitle=Recent+progress+in+the+epidemiology+of+atrial+fibrillation&amp;rft.title=Curr+Opin+Cardiol&amp;rft.jtitle=Curr+Opin+Cardiol&amp;rft.date=2005&amp;rft.volume=20&amp;rft.issue=1&amp;rft.au=Greenlee+RT%2C+Vidaillet+H&amp;rft.pages=7-14">&#160;</span> <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15596953" class="external" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=15596953">PMID 15596953</a></li>
</ul>
<p><a name="External_links" id="External_links"></a></p>
<h2><span class="editsection">[<a href="../../../a/t/r/Atrial_fibrillation.html" title="Edit section: External links">edit</a>]</span> <span class="mw-headline">External links</span></h2>
<ul>
<li><a href="http://www.afibfacts.com/What_is_Atrial_Fibrillation/" class="external text" title="http://www.afibfacts.com/What_is_Atrial_Fibrillation/" rel="nofollow">About Atrial Fibrillation</a></li>
<li><a href="http://www.afibbers.org/" class="external text" title="http://www.afibbers.org/" rel="nofollow">Hans Larsen's Site for Afibbers, Families and Researchers</a></li>
<li><a href="http://www.a-fib.com/" class="external text" title="http://www.a-fib.com/" rel="nofollow">Atrial Fibrillation Resources for Patients</a></li>
<li><a href="http://www.italheartj.org/abstract/I_H_J_2002_3_571-578.htm" class="external text" title="http://www.italheartj.org/abstract/I_H_J_2002_3_571-578.htm" rel="nofollow">Hybrid therapy of Atrial Fibrillation</a></li>
<li><a href="http://www.healthsystem.virginia.edu/Internet/afibcenter/afib_center.cfm" class="external text" title="http://www.healthsystem.virginia.edu/Internet/afibcenter/afib_center.cfm" rel="nofollow">Atrial Fibrillation Center at the University of Virginia</a></li>
<li><a href="http://www.rwjuh.edu/medical_services/min_invasive_atrial_fibrillation.html" class="external text" title="http://www.rwjuh.edu/medical_services/min_invasive_atrial_fibrillation.html" rel="nofollow">Minimally Invasive Treatment for Atrial Fibrillation at Robert Wood Johnson University Hospital</a></li>
<li><a href="http://www.londonafcentre.co.uk" class="external text" title="http://www.londonafcentre.co.uk" rel="nofollow">London Atrial Fibrillation Centre</a></li>
<li><a href="http://www.afadvisor.org" class="external text" title="http://www.afadvisor.org" rel="nofollow">Atrial Fibrillation Information - AF Advisor</a></li>
<li><a href="http://www.afibsupport.com" class="external text" title="http://www.afibsupport.com" rel="nofollow">AfibSupport Yahoo Groups support group</a></li>
<li><a href="http://www.aral.org.uk/html/atrial_fibrillation.html" class="external text" title="http://www.aral.org.uk/html/atrial_fibrillation.html" rel="nofollow">Atrial Fibrillation Patient Information</a> at Arrhythmia Alliance</li>
<li><a href="http://www.clotcare.com/clotcare/postings.aspx?by=condition&amp;conditionid=2&amp;word=Atrial%20Fibrillation%20(A.fib.%20or%20AF)" class="external text" title="http://www.clotcare.com/clotcare/postings.aspx?by=condition&amp;conditionid=2&amp;word=Atrial%20Fibrillation%20(A.fib.%20or%20AF)" rel="nofollow">Atrial Fibrillation Resources for Patients &amp; Healthcare Providers</a> - ClotCare.com</li>
</ul>

<!-- 
Pre-expand include size: 65302 bytes
Post-expand include size: 31113 bytes
Template argument size: 22985 bytes
Maximum: 2048000 bytes
-->
<div class="printfooter">
Retrieved from "<a href="http://en.wikipedia.org../../../a/t/r/Atrial_fibrillation.html">http://en.wikipedia.org../../../a/t/r/Atrial_fibrillation.html</a>"</div>
	    <div id="catlinks"><p class='catlinks'><a href="../../../c/a/t/Special%7ECategories_101d.html" title="Special:Categories">Category</a>: <span dir='ltr'><a href="../../../c/a/r/Category%7ECardiac_electrophysiology_f2fe.html" title="Category:Cardiac electrophysiology">Cardiac electrophysiology</a></span></p></div>	    <!-- end content -->
	    <div class="visualClear"></div>
	  </div>
	</div>
      </div>
      <div id="column-one">
	<div id="p-cactions" class="portlet">
	  <h5>Views</h5>
	  <ul>
	    <li id="ca-nstab-main"
	       class="selected"	       ><a href="../../../a/t/r/Atrial_fibrillation.html">Article</a></li><li id="ca-talk"
	       	       ><a href="../../../a/t/r/Talk%7EAtrial_fibrillation_50b7.html">Discussion</a></li><li id="ca-current"
	       	       ><a href="http://en.wikipedia.org/wiki/Atrial_fibrillation">Current revision</a></li>	  </ul>
	</div>
	<div class="portlet" id="p-logo">
	  <a style="background-image: url(../../../images/wiki-en.png);"
	    href="../../../index.html"
	    title="Main Page"></a>
	</div>
	<script type="text/javascript"> if (window.isMSIE55) fixalpha(); </script>
		<div class='portlet' id='p-navigation'>
	  <h5>Navigation</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-Main-page"><a href="../../../index.html">Main page</a></li>
	     	      <li id="n-Contents"><a href="../../../c/o/n/Wikipedia%7EContents_3181.html">Contents</a></li>
	     	      <li id="n-Featured-content"><a href="../../../f/e/a/Wikipedia%7EFeatured_content_24ba.html">Featured content</a></li>
	     	      <li id="n-currentevents"><a href="../../../c/u/r/Portal%7ECurrent_events_bb60.html">Current events</a></li>
	     	    </ul>
	  </div>
	</div>
		<div class='portlet' id='p-interaction'>
	  <h5>interaction</h5>
	  <div class='pBody'>
	    <ul>
	    	      <li id="n-About-Wikipedia"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html">About Wikipedia</a></li>
	     	      <li id="n-portal"><a href="../../../c/o/m/Wikipedia%7ECommunity_Portal_6a3c.html">Community portal</a></li>
	     	      <li id="n-contact"><a href="../../../c/o/n/Wikipedia%7EContact_us_afd6.html">Contact us</a></li>
	     	      <li id="n-sitesupport"><a href="http://wikimediafoundation.org/wiki/Fundraising">Make a donation</a></li>
	     	      <li id="n-help"><a href="../../../c/o/n/Help%7EContents_22de.html">Help</a></li>
	     	    </ul>
	  </div>
	</div>
		<div id="p-search" class="portlet">
	  <h5><label for="searchInput">Search</label></h5>
	  <div id="searchBody" class="pBody">
	    <form action="javascript:goToStatic(3)" id="searchform"><div>
	      <input id="searchInput" name="search" type="text"
	        accesskey="f" value="" />
	      <input type='submit' name="go" class="searchButton" id="searchGoButton"
	        value="Go" />
	    </div></form>
	  </div>
	</div>
	<div id="p-lang" class="portlet">
	  <h5>In other languages</h5>
	  <div class="pBody">
	    <ul>
	      	      <li>
	      <a href="../../../../de/v/o/r/Vorhofflimmern.html">Deutsch</a>
	      </li>
	      	      <li>
	      <a href="../../../../fr/f/i/b/Fibrillation_auriculaire.html">Français</a>
	      </li>
	      	      <li>
	      <a href="../../../../nl/b/o/e/Boezemfibrilleren.html">Nederlands</a>
	      </li>
	      	      <li>
	      <a href="../../../../ja/%E5%BF%83/%E6%88%BF/%E7%B4%B0/%E5%BF%83%E6%88%BF%E7%B4%B0%E5%8B%95.html">日本語</a>
	      </li>
	      	      <li>
	      <a href="../../../../no/a/t/r/Atrieflimmer.html">‪Norsk (bokmål)‬</a>
	      </li>
	      	      <li>
	      <a href="../../../../pl/m/i/g/Migotanie_przedsionk%C3%B3w.html">Polski</a>
	      </li>
	      	      <li>
	      <a href="../../../../fi/e/t/e/Eteisv%C3%A4rin%C3%A4.html">Suomi</a>
	      </li>
	      	    </ul>
	  </div>
	</div>
	      </div><!-- end of the left (by default at least) column -->
      <div class="visualClear"></div>
      <div id="footer">
    <div id="f-poweredbyico"><a href="http://www.mediawiki.org/"><img src="../../../skins/common/images/poweredby_mediawiki_88x31.png" alt="Powered by MediaWiki" /></a></div>	<div id="f-copyrightico"><a href="http://wikimediafoundation.org/"><img src="../../../images/wikimedia-button.png" border="0" alt="Wikimedia Foundation"/></a></div>	<ul id="f-list">
	  	  	  <li id="f-credits">This page was last modified 23:46, 24 March 2007 by Wikipedia user Nbrysiewicz. Based on work by Wikipedia user(s) <a href="../../../d/a/n/User%7EDan_D._Ric_0933.html" title="User:Dan D. Ric">Dan D. Ric</a>, <a href="../../../v/e/i/User%7EVeinor_0082.html" title="User:Veinor">Veinor</a>, <a href="../../../d/l/o/User%7EDlodge_1452.html" title="User:Dlodge">Dlodge</a>, <a href="../../../l/u/n/User%7ELuna_Santin_1cab.html" title="User:Luna Santin">Luna Santin</a>, Sh111496, <a href="../../../r/j/a/User%7ERJASE1_c81d.html" title="User:RJASE1">RJASE1</a>, <a href="../../../b/u/r/User%7EBurlywood_b74b.html" title="User:Burlywood">Burlywood</a>, Mbwalker, <a href="../../../d/o/c/User%7EDoctormatt_2991.html" title="User:Doctormatt">Doctormatt</a>, Tadler53033, Maryskole, <a href="../../../a/t/o/User%7EAtom_cz_dd70.html" title="User:Atom cz">Atom cz</a>, <a href="../../../l/e/a/User%7ELeaderofearth_d7b0.html" title="User:Leaderofearth">Leaderofearth</a>, ArrhythmiaAlliance, <a href="../../../k/a/i/User%7EKaiserbBot_1c36.html" title="User:KaiserbBot">KaiserbBot</a>, <a href="../../../a/2E/_/User%7EA._B._b9cc.html" title="User:A. B.">A. B.</a>, Biancamed, Freezor, <a href="../../../j/f/d/User%7EJfdwolff_9ea6.html" title="User:Jfdwolff">Jfdwolff</a>, <a href="../../../i/a/n/User%7EIan_Dalziel_b73f.html" title="User:Ian Dalziel">Ian Dalziel</a>, <a href="../../../b/r/i/User%7EBrighterorange_f618.html" title="User:Brighterorange">Brighterorange</a>, <a href="../../../j/o/n/User%7EJonHarder_ef53.html" title="User:JonHarder">JonHarder</a>, <a href="../../../c/e/l/User%7ECelian_b37e.html" title="User:Celian">Celian</a>, <a href="../../../k/s/h/User%7EKsheka_e2cf.html" title="User:Ksheka">Ksheka</a>, <a href="../../../t/h/i/User%7EThijs%21bot_bdf4.html" title="User:Thijs!bot">Thijs!bot</a>, <a href="../../../a/n/d/User%7EAndyRudin_8f80.html" title="User:AndyRudin">AndyRudin</a>, <a href="../../../m/w/a/User%7EMwanner_e32b.html" title="User:Mwanner">Mwanner</a>, <a href="../../../g/a/k/User%7EGak_da6b.html" title="User:Gak">Gak</a>, <a href="../../../a/r/c/User%7EArcadian_5c4b.html" title="User:Arcadian">Arcadian</a>, Powers.andy, <a href="../../../z/y/r/User%7EZyryab_fb23.html" title="User:Zyryab">Zyryab</a>, <a href="../../../d/a/n/User%7EDanielrocks123_a894.html" title="User:Danielrocks123">Danielrocks123</a>, <a href="../../../a/p/e/User%7EApers0n_d5e5.html" title="User:Apers0n">Apers0n</a>, <a href="../../../w/o/u/User%7EWouterstomp_b006.html" title="User:Wouterstomp">Wouterstomp</a>, Scottybowl, <a href="../../../b/a/d/User%7EBadagnani_11ed.html" title="User:Badagnani">Badagnani</a>, <a href="../../../o/l/d/User%7EOldakQuill_3b15.html" title="User:OldakQuill">OldakQuill</a>, <a href="../../../y/u/r/User%7EYurikBot_b393.html" title="User:YurikBot">YurikBot</a>, <a href="../../../l/i/g/User%7ELigulembot_623f.html" title="User:Ligulembot">Ligulembot</a>, <a href="../../../o/r/p/User%7EOrphanBot_88cf.html" title="User:OrphanBot">OrphanBot</a>, <a href="../../../r/e/w/User%7ERewster_1ad1.html" title="User:Rewster">Rewster</a>, <a href="../../../r/e/x/User%7ERexNL_e4e0.html" title="User:RexNL">RexNL</a>, <a href="../../../e/s/k/User%7EESkog_db4a.html" title="User:ESkog">ESkog</a>, Bldavids, <a href="../../../i/n/v/User%7EInvictaHOG_427a.html" title="User:InvictaHOG">InvictaHOG</a>, <a href="../../../d/o/c/User%7EDocJohnny_db09.html" title="User:DocJohnny">DocJohnny</a>, <a href="../../../m/a/t/User%7EMattopaedia_a144.html" title="User:Mattopaedia">Mattopaedia</a>, <a href="../../../a/n/d/User%7EAndrew73_a1aa.html" title="User:Andrew73">Andrew73</a>, <a href="../../../j/a/m/User%7EJamesmcclelland_3200.html" title="User:Jamesmcclelland">Jamesmcclelland</a>, <a href="../../../a/2E/_/User%7EA._Rad_89e2.html" title="User:A. Rad">A. Rad</a>, <a href="../../../d/i/b/User%7EDiberri_3d04.html" title="User:Diberri">Diberri</a>, <a href="../../../c/y/b/User%7ECybergoth_b23c.html" title="User:Cybergoth">Cybergoth</a>, <a href="../../../s/a/r/User%7ESarekOfVulcan_fb73.html" title="User:SarekOfVulcan">SarekOfVulcan</a>, <a href="../../../m/a/i/User%7EMailer_diablo_6ffa.html" title="User:Mailer diablo">Mailer diablo</a>, <a href="../../../a/x/e/User%7EAxelBoldt_4306.html" title="User:AxelBoldt">AxelBoldt</a>, <a href="../../../a/a/a/User%7EAAAAA_5820.html" title="User:AAAAA">AAAAA</a>, AustinKnight, <a href="../../../l/a/p/User%7ELapappey_aeaf.html" title="User:Lapappey">Lapappey</a>, Wkruse, Faderrattnerb, <a href="../../../a/x/l/User%7EAxl_2118.html" title="User:Axl">Axl</a>, <a href="../../../t/a/r/User%7ETarek_3966.html" title="User:Tarek">Tarek</a>, <a href="../../../h/a/d/User%7EHadal_a4d0.html" title="User:Hadal">Hadal</a>, <a href="../../../m/e/h/User%7EMehrenberg_7ccc.html" title="User:Mehrenberg">Mehrenberg</a>, <a href="../../../k/a/t/User%7EKate_3866.html" title="User:Kate">Kate</a>, <a href="../../../p/f/h/User%7EPFHLai_0319.html" title="User:PFHLai">PFHLai</a>, <a href="../../../t/h/e/User%7EThe_Anome_61a9.html" title="User:The Anome">The Anome</a> and <a href="../../../w/r/i/User%7EWriterite_7d47.html" title="User:Writerite">Writerite</a> and Anonymous user(s) of Wikipedia.</li>	  <li id="f-copyright">All text is available under the terms of the <a class='internal' href="../../../t/e/x/Wikipedia%7EText_of_the_GNU_Free_Documentation_License_702a.html" title="Wikipedia:Text of the GNU Free Documentation License">GNU Free Documentation License</a>. (See <b><a class='internal' href="../../../c/o/p/Wikipedia%7ECopyrights_92c4.html" title="Wikipedia:Copyrights">Copyrights</a></b> for details.) <br /> Wikipedia&reg; is a registered trademark of the <a href="http://www.wikimediafoundation.org">Wikimedia Foundation, Inc</a>., a US-registered <a class='internal' href="../../../5/0/1/501%28c%29.html#501.28c.29.283.29" title="501(c)(3)">501(c)(3)</a> <a href="http://wikimediafoundation.org/wiki/Deductibility_of_donations">tax-deductible</a> <a class='internal' href="../../../n/o/n/Non-profit_organization.html" title="Non-profit organization">nonprofit</a> <a href="../../../c/h/a/Charitable_organization.html" title="Charitable organization">charity</a>.<br /></li>	  <li id="f-about"><a href="../../../a/b/o/Wikipedia%7EAbout_8d82.html" title="Wikipedia:About">About Wikipedia</a></li>	  <li id="f-disclaimer"><a href="../../../g/e/n/Wikipedia%7EGeneral_disclaimer_3e44.html" title="Wikipedia:General disclaimer">Disclaimers</a></li>	  	</ul>
      </div>
    </div>
  </body>
</html>
